Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
LeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Immunovant (IMVT) Shares Outstanding (2018 - 2026)

Immunovant filings provide 8 years of Shares Outstanding readings, the most recent being $10000.0 for Q4 2025.

  • Quarterly Shares Outstanding fell 99.99% to $10000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10000.0 through Dec 2025, down 99.99% year-over-year, with the annual reading at $10000.0 for FY2025, 99.99% down from the prior year.
  • Shares Outstanding hit $10000.0 in Q4 2025 for Immunovant, roughly flat from $10000.0 in the prior quarter.
  • Across five years, Shares Outstanding topped out at $171.1 million in Q2 2025 and bottomed at $10000.0 in Q1 2021.
  • Average Shares Outstanding over 5 years is $66.6 million, with a median of $57.6 million recorded in 2021.
  • The largest annual shift saw Shares Outstanding soared 1471935.65% in 2024 before it plummeted 99.99% in 2025.
  • Immunovant's Shares Outstanding stood at $115.1 million in 2021, then increased by 12.29% to $129.3 million in 2022, then tumbled by 99.99% to $10000.0 in 2023, then soared by 1471935.65% to $147.2 million in 2024, then plummeted by 99.99% to $10000.0 in 2025.
  • Per Business Quant, the three most recent readings for IMVT's Shares Outstanding are $10000.0 (Q4 2025), $174.5 million (Q3 2025), and $171.1 million (Q2 2025).